Donald Bobo Jr Sells 22,680 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.41 during midday trading on Thursday, hitting $80.85. The company’s stock had a trading volume of 3,303,021 shares, compared to its average volume of 4,588,320. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The stock has a market capitalization of $46.61 billion, a price-to-earnings ratio of 44.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. The company’s fifty day simple moving average is $81.78 and its two-hundred day simple moving average is $81.72.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $27,000. True Wealth Design LLC boosted its position in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $28,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.